ALLO News and Press, Allogene Therapeutics Inc. From 06/14/23

SOUTH SAN FRANCISCO, Calif., June 14, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, announced that its Chief Financial Officer, Eric T. Schmidt, Ph...

Long-Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrates Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to Approved Autologous Therapies Presentation Recaps 12 Patients Treated with Phase 2 Dose Regimen and Includes Additional Data on All 33 CA...

Long Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrate Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to Approved Autologous Therapies Presentation Focused on Patients (n=12) Treated with Phase 2 Regimen 67% Overall Response Rate (ORR) a...

2023-05-19 07:03:47 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips One of the places to find the best stocks to short are by viewing the Short Interest tables of major financial publications like MarketWatch and the Wall Street Journal. ...

Data Will Also Be Presented in a Poster Session at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 3, 2023 SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the ...

2023-05-03 23:49:06 ET Allogene Therapeutics, Inc. (ALLO) Q1 2023 Earnings Conference Call May 3, 2023, 5:00 PM ET Company Participants Christine Cassiano - Chief Communications Officer Dr. David Chang - President and CEO Dr. Zachary Roberts - Executive Vice Pres...

2023-05-03 16:35:34 ET Allogene Therapeutics press release ( NASDAQ: ALLO ): Q1 GAAP EPS of -$0.68 misses by $0.06 . Revenue of $0.05M (-16.7% Y/Y) beats by $0.04M . Research and development expenses were $80.2 million for the first quarter of 2023, which inclu...

Enrollment Ongoing in Industry’s First Potentially Pivotal Phase 2 Allogeneic CAR T Trial, ALPHA2, in Relapsed/Refractory Large B Cell Lymphoma Initiated Phase 2 EXPAND Trial to Support Licensure of ALLO-647 as a Lymphodepleting Agent for ALLO-501A Announced American Society of Cli...

SOUTH SAN FRANCISCO, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced it will present updated data from the Pha...

Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET SOUTH SAN FRANCISCO, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for ...